U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07646353) titled 'First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults' on June 09.
Brief Summary: This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.
Study Start Date: June 12
Study Type: INTERVENTIONAL
Condition:
Malaria, Falciparum
Intervention:
BIOLOGICAL: GSK4425689A SC
Participants receive GSK4425689A SC.
BIOLOGICAL: GSK4425689A IV
Participants receive GSK4425689A IV.
DRUG: Placebo
Participants receive Placebo in the same volume and r...